Desmethylclomipramine induces the accumulation of autophagy markers by blocking autophagic flux
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Alterations in the autophagic pathway are associated with the onset and progression of various diseases. However, despite the therapeutic potential for pharmacological modulators of autophagic flux, few such compounds have been characterised. Here we show that clomipramine, an FDA-approved drug long used for the treatment of psychiatric disorders, and its active metabolite desmethylclomipramine (DCMI) interfere with autophagic flux. Treating cells with DCMI caused a significant and specific increase in autophagosomal markers and a concomitant blockage of the degradation of autophagic cargo. This observation might be relevant in therapy in which malignant cells exploit autophagy to survive stress conditions, rendering them more susceptible to the action of cytotoxic agents. In accordance, DCMI-mediated obstruction of autophagic flux increased the cytotoxic effect of chemotherapeutic agents. Collectively, our studies describe a new function of DCMI that can be exploited for the treatment of pathological conditions in which manipulation of autophagic flux is thought to be beneficial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 4×
“1 (Biosoft), which performs multiple drug dose-effect calculations using the median effects method described by Chou and Talalay (Chou and Talalay, 1984), to determine the CI of the combined treatment of doxorubicin and DCMI.”
MethodInfluentialRavikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347 · cited 1×
“…of punctate LC3 staining upon pharmacological induction of autophagy with rapamycin, one of best-characterised drugs that enhances autophagy Jo ur na l o f C el l S ci en ce 3333Clomipramine blocks autophagic flux by inhibiting mTOR (mammalian target of rapamycin) (Ravikumar et al., 2004).”
BackgroundGuidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes
Klionsky, D. J., Abeliovich, H., Agostinis, P., Agrawal, D. K., Aliev, G., Askew, D. S., Baba, M., Baehrecke, E. H., Bahr, B. A., Ballabio, A., et al. (2008) · Autophagy · doi:10.4161/auto.5338 · Cited by 2,230 · cited 3×
“Changes in the autophagic flux, defined as the equilibrium between autophagosome formation and clearance by lysosomes, can also occur from impairment of the ability to eliminate autophagic structures from the cytosol through the lysosomal compartment (Klionsky et al., 2008).”
BackgroundHomeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice.
Komatsu, M., Waguri, S., Koike, M., Sou, Y.-S., Ueno, T., Hara, T., Mizushima, N., Iwata, J.-I., Ezaki, J., Murata, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.035 · Cited by 2,124
Mathew, R., Karantza-Wadsworth, V., & White, E. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2254 · Cited by 1,798 · cited 2×
“In fact, although our understanding of the role of autophagy in tumour biology is at an early stage, increasing evidence indicates that autophagy might protect cancer cells against the effect of cytotoxic compounds and allow continued survival of transformed cells (Kondo et al., 2005; Levine, 2007; Mathew et al., 2007…”
BackgroundStructural Basis for Sorting Mechanism of p62 in Selective Autophagy
Ichimura, Y., Kumanomidou, T., Sou, Y.-S., Mizushima, T., Ezaki, J., Ueno, T., Kominami, E., Yamane, T., Tanaka, K., & Komatsu, M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802182200 · Cited by 803
Methods for Monitoring Autophagy from Yeast to Human
Klionsky, D. J., Cuervo, A. M., & Seglen, P. O. (2007) · Autophagy · doi:10.4161/auto.3678 · Cited by 656
Autophagy: Basic Principles and Relevance to Disease
Kundu, M., & Thompson, C. B. (2008) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathmechdis.2.010506.091842 · Cited by 523 · cited 1×
“Therefore, it is not surprising that alterations in autophagy have been associated with different human pathological conditions (Kundu and Thompson, 2008; Levine and Kroemer, 2008; Mizushima et al., 2008).”
BackgroundMeschini, S., Condello, M., Calcabrini, A., Marra, M., Formisano, G., Lista, P., De Milito, A., Federici, E., & Arancia, G. (2008) · Autophagy · doi:10.4161/auto.6952 · Cited by 72
Cited by
The Role of Autophagy in Cancer: Therapeutic Implications
Yang, Z. J., Chee, C. E., Huang, S., & Sinicrope, F. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0047 · Cited by 1,215
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
Feitelson, M. A., Arzumanyan, A., Kulathinal, R. J., Blain, S. W., Holcombe, R. F., Mahajna, J., Marino, M., Martinez-Chantar, M. L., Nawroth, R., Sanchez-Garcia, I., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.006 · Cited by 778
Autophagy: The spotlight for cellular stress responses
Ravanan, P., Srikumar, I. F., & Talwar, P. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.08.029 · Cited by 580
Petersen, N. H. T., Olsen, O. D., Groth-Pedersen, L., Ellegaard, A.-M., Bilgin, M., Redmer, S., Ostenfeld, M. S., Ulanet, D., Dovmark, T. H., Lønborg, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.003 · Cited by 337
Pasquier, B. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2104-y · Cited by 329
“Its active metabolite, desmethylclomipramine have been shown to interfere with autophagic flux by blocking autophagosome-lysosome fusion [108].”
BackgroundNguyen, H. G., Yang, J. C., Kung, H.-J., Shi, X.-B., Tilki, D., Lara, P. N., DeVere White, R. W., Gao, A. C., & Evans, C. P. (2014) · Oncogene · doi:10.1038/onc.2014.25 · Cited by 212
Gassen, N. C., Hartmann, J., Zschocke, J., Stepan, J., Hafner, K., Zellner, A., Kirmeier, T., Kollmannsberger, L., Wagner, K. V., Dedic, N., et al. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001755 · Cited by 177
“We analyzed whether these pathways involve autophagic events based on reports stating that some antidepressants alter at least the initial processes of autophagy [14,15].”
BackgroundAutophagy: A Druggable Process
Morel, E., Mehrpour, M., Botti, J., Dupont, N., Hamaï, A., Nascimbeni, A. C., & Codogno, P. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104936 · Cited by 168
Jiang, P., Guo, Y., Dang, R., Yang, M., Liao, D., Li, H., Sun, Z., Feng, Q., & Xu, P. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1013-4 · Cited by 139
“Intriguingly, desmethylclomipramine blocks autophagic flux in tumor cells, thus potentiating the cytotoxic effect of chemotherapeutic agents [37, 38].”
Autophagy and its implication in Chinese hamster ovary cell culture
Kim, Y. J., Baek, E., Lee, J. S., & Lee, G. M. (2013) · Biotechnology Letters · doi:10.1007/s10529-013-1276-5 · Cited by 40
“Desmethylclomipramine Autophagosome formation blocker Rossi et al. (2009)”
Metadata
- Authors
- Rossi, M., Munarriz, E. R., Bartesaghi, S., Milanese, M., Dinsdale, D., Guerra-Martin, M. A., Bampton, E. T. W., Glynn, P., Bonanno, G., Knight, R. A., Nicotera, P., & Melino, G.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2009-09-15
- Volume
- 122
- Issue
- 18
- Pages
- 3330-3339
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W2158034667
- Cited by
- 124
- References
- 9
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.